ACAD ACADIA Pharmaceuticals Inc. - Fundamental Analysis
BULLISH
Sign in to save
Save this symbol to a watchlist or track a position.
ACAD Stock | Fundamental Analysis & Investment Insights
NASDAQ
Healthcare
Biotechnology
Current Price
Live
$23.99
Analyst Target
$31.21
+30.1%
Upside
52W High
$28.35
52W Low
$13.4
At a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
Powered by advanced machine learning algorithms
Confidence Score
87%
Analysis Accuracy
ACAD demonstrates strong financial health with a Piotroski F-Score of 7/9, indicating robust operational and profitability fundamentals. The company exhibits exceptional earnings growth (112.8% YoY) and consistent earnings surprises averaging +69.6% over the last four quarters, signaling strong market confidence. Despite a bearish insider sentiment due to recent selling activity, the stock trades below its intrinsic value of $45.73 and Graham Number of $13.75, suggesting significant upside potential. The absence of a Z-Score is not a concern given the company's low debt and strong liquidity. Analysts maintain a buy consensus with a target price of $31.21, supporting a bullish outlook.
Key Strengths
Piotroski F-Score of 7/9 indicates strong financial health and operational efficiency
Exceptional earnings growth of 112.8% YoY and 119.1% Q/Q, with consistent beat rates
High gross margin (59.00%) and strong ROE (34.95%) reflect efficient capital use
Minimal debt (Debt/Equity: 0.06) and strong liquidity (Current Ratio: 3.02)
Intrinsic value ($45.73) significantly exceeds current price ($23.99), indicating undervaluation
Key Risks
Bearish insider sentiment with $1.3M in sales over 6 months, particularly from CFO and director
No dividend and zero payout ratio, limiting income appeal
Forward P/E of 30.85 is elevated relative to current P/E, suggesting high growth expectations
Lack of PEG ratio and limited cash flow data hinder full valuation clarity
High volatility in price performance (6M: -6.8%, 1M: -10.3%) despite long-term gains
AI Fair Value Estimate
Based on comprehensive analysis
$45.73
+90.6% above current price
Performance Snowflake
Multi-dimensional AI analysis across 5 key categories
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Historical Performance Trends
Long-term financial metrics and growth patterns
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability, Growth & Financial Health
Detailed profit margins, ROE, debt ratios, and liquidity metrics
Sector Comparison & Peer Analysis
Compare ACAD against industry averages and similar companies
Insider Trading & Analyst Ratings
Track insider transactions and Wall Street analyst recommendations
Past News Coverage
Recent headlines mentioning ACAD from our newsroom.
Newest → oldest
No matching news yet.